Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Core Viewpoint - Calidi Biotherapeutics, Inc. announced a reverse stock split at a ratio of 1-for-12 to optimize market dynamics and broaden investor appeal, effective August 5, 2025 [1][2]. Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to disease sites, utilizing its proprietary Redtail platform [6][7]. - The Redtail platform is designed to create viral vectors that evade immune detection, allowing for effective delivery of virotherapy to tumor sites [6]. Reverse Stock Split Details - The reverse stock split will consolidate every twelve pre-split shares into one post-split share, with fractional shares rounded up to the nearest whole share at the participant level [3][4]. - The split was approved by stockholders on July 9, 2025, and by the Board of Directors on July 11, 2025 [2]. - The new CUSIP number for the common stock will be 320703 408 following the split [1]. Stockholder Information - Registered stockholders with book-entry shares will not need to take action to receive post-split shares, while those with shares in certificate form will receive instructions for exchanging their certificates [5].